1)Torizuka T, Tamaki N, Inokuma T, et al:In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811-1817, 1995
2)村上康二,山崎英玲奈,北島一宏,他:肝細胞癌の診断と治療 最新動向と将来展望 PET.臨放 54:357-366,2009
3)Wudel LJ Jr, Delbeke D, Morris D, et al:The role of[18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 69:117-126, 2003
4)Trojan J, Schroeder O, Raedle J, et al:Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 94:3314-3319, 1999
5)土井隆一郎,瀬尾 智,上 和広,他:各臓器・疾患におけるPET診断の意義 肝胆膵.臨消内科 24:325-337,2009
6)Seo S, Hatano E, Higashi T, et al:Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 13(2 Pt 1):427-433, 2007
7)Higashi T, Hatano E, Ikai I, et al:FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging:2009 Oct 17.[Epub ahead of print]
8)Sugiyama M, Sakahara H, Torizuka T, et al:18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 39:961-968, 2004
9)Han AR, Gwak GY, Choi MS, et al:The clinical value of 18F-FDG PET/CT for investigating unexplained serum AFP elevation following interventional therapy for hepatocellular carcinom. Hepatogastroenterology. 56:1111-1116, 2009
C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44:213-221, 2003
F-FDG PET. J Nucl Med 49:1245-1248, 2008